Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Cuproptosis: mechanisms and links with cancers

Xie, J., Yang, Y., Gao, Y., & He, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01732-y · Cited by 843

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Wang, Z., Cui, C., Yao, J., Zhang, Y., Li, M., Feng, J., Yang, S., Fan, Y., Shi, J., Zhang, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.007 · Cited by 559

Application of PD-1 Blockade in Cancer Immunotherapy

Wu, X., Gu, Z., Yang, C., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 541

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419

Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment

Marzagalli, M., Ebelt, N. D., & Manuel, E. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.002 · Cited by 358

Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)

Yang, L., Xie, H., Li, Y., Wang, X., Liu, X., & Mai, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8293 · Cited by 327

Antitumor effects of immunity-enhancing traditional Chinese medicine

Wang, Y., Zhang, Q., Chen, Y., Liang, C.-L., Liu, H., Qiu, F., & Dai, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109570 · Cited by 293

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy

Cai, J., Wang, D., Zhang, G., & Guo, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221340 · Cited by 251

Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages

Chen, Y., Liu, Y., Wang, Y., Chen, X., Wang, C., Chen, X., Yuan, X., Liu, L., Yang, J., & Zhou, X. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02201-4 · Cited by 228

CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner

Zhang, Q.-F., Li, J., Jiang, K., Wang, R., Ge, J.-L., Yang, H., Liu, S.-J., Jia, L.-T., Wang, L., & Chen, B.-L. (2020) · Theranostics · doi:10.7150/thno.44871 · Cited by 177

Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study

Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., Sharon, E., STREICHER, H. Z., Li, S., McShane, L. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00818 · Cited by 170

PD-1/PD-L1 Inhibitors in Cervical Cancer

Liu, Y., Wu, L., Tong, R., Yang, F., Yin, L., Li, M., You, L., Xue, J., & Lü, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00065 · Cited by 153

Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells

Ke, M., Zhang, Z., Xu, B.-Y., Zhao, S., Ding, Y., Wu, X., Wu, R., Lv, Y., & Dong, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105824 · Cited by 145

Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy

Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy

Xiong, W., Qi, L., Jiang, N., Zhao, Q., Chen, L., Jiang, X., Li, Y., Zhou, Z., & Shen, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21743 · Cited by 134

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers

Wu, H., Wang, Z., Zhao, Q., Chen, D., He, M.-M., Yang, L.-P., Wang, Y., Jin, Y., Ren, C., Luo, H., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.116 · Cited by 132

Peripheral T cell lymphomas: from the bench to the clinic

Fiore, D., Cappelli, L. V., Broccoli, A., Zinzani, P. L., Chan, W. C., & Inghirami, G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0247-0 · Cited by 131

Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Qin, M., Cao, Q., Zheng, S., Tian, Y., Zhang, H., Xie, J., Xie, H., Liu, Y., Zhao, Y., & Gong, P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00312 · Cited by 110

Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model

Wu, J., Zhao, X., Sun, Q., Jiang, Y., Zhang, W., Luo, J., & Li, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109746 · Cited by 110

Monoclonal Antibodies: Past, Present and Future

Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 120

Nanotransferrin-Based Programmable Catalysis Mediates Three-Pronged Induction of Oxidative Stress to Enhance Cancer Immunotherapy

Bai, S., Lu, Z., Jiang, Y., Shi, X., Xu, D., Shi, Y., Lin, G., Liu, C., Zhang, Y., & Liu, G. (2021) · ACS Nano · doi:10.1021/acsnano.1c08619 · Cited by 104

Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy

Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 115

Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano‐immunotherapy in Breast Cancer Lung Metastasis

Mpekris, F., Panagi, M., Voutouri, C., Martin, J. D., Samuel, R., Takahashi, S., Gotohda, N., Suzuki, T., Papageorgis, P., Demetriou, P., et al. (2020) · Advanced Science · doi:10.1002/advs.202001917 · Cited by 104

Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs

Bailly, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117403 · Cited by 107

Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study

Dave, K., Ali, A. A., & Magalhães, M. A. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-66257-6 · Cited by 104

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

Taylor, M. A., Hughes, A. M., Walton, J. B., Coenen-Stass, A. M. L., Magiera, Ł., Mooney, L. M., Bell, S., Staniszewska, A. D., Sandin, L. C., Barry, S. T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0794-7 · Cited by 98

Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines

Sun, Z., Sun, X., Chen, Z., Du, J., & Wu, Y. (2021) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10334-5 · Cited by 106

The Emerging Role of YAP/TAZ in Tumor Immunity

Pan, Z., Tian, Y., Cao, C., & Niu, G. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0375 · Cited by 99

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects

Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 99

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy

Loizides, S., & Constantinidou, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1095839 · Cited by 90

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer

Papadaki, M. A., Koutsopoulos, A. V., Tsoulfas, P. G., Lagoudaki, E. D., Aggouraki, D., Monastirioti, A. A., Koutoulaki, C., Apostolopoulou, C. A., Merodoulaki, A. C., Papadaki, C., et al. (2020) · Cancers · doi:10.3390/cancers12020376 · Cited by 86

Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk

Ait‐Oufella, H., Libby, P., & Tedgui, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311998 · Cited by 84

Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis

Ghouse, S. M., Nguyen, H.-M., Bommareddy, P. K., Guz-Montgomery, K., & Saha, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00384 · Cited by 78

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer

Yang, H., Zhang, X., Lao, M., Sun, K., He, L., Xu, J., Duan, Y., Chen, Y., Ying, H., Li, M., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01102-z · Cited by 78

Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective

Muthukutty, P., & Yoo, S. Y. (2023) · Viruses · doi:10.3390/v15081645 · Cited by 84

Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress

Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 86

Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma

Hu, M., Yang, J. F., Qu, L., Deng, X., Duan, Z., Fu, R., Liang, L., & Fan, D. (2019) · Food & Function · doi:10.1039/c9fo02166c · Cited by 77

The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer

Tang, Y., Zhang, P., Wang, Y., Wang, J., Su, M., Wang, Y., Zhou, L., Zhou, J., Xiong, W., Zeng, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00604 · Cited by 81

MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β

Du, F., Qi, X., Zhang, A., Sui, F., Wang, X., Proud, C. G., Lin, C., Fan, X., & Li, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00670-3 · Cited by 78

Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α

Mo, D., Zhu, H., Wang, J., Hao, H., Guo, Y., Wang, J., Han, X., Zou, L., Li, Z., Yao, H., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048905 · Cited by 72

Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade

Chuang, Y.-C., Tseng, J., Huang, L.-R., Huang, C., Huang, C. F., & Chuang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01075 · Cited by 74

Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Qin, M., Meng, Y., Yang, H., Liu, L., Zhang, H., Wang, S., Liu, C., Wu, X., Wu, D., Tian, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01958 · Cited by 71

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity

Lemos, H. D. P., Ou, R., McCardle, C., Lin, Y., Calver, J., Minett, J., Chadli, A., Huang, L., & Mellor, A. L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001182 · Cited by 69

Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers

Liu, Q., Jiang, L., Li, K., Li, H., Lv, G., Lin, J., & Qiu, L. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02818-y · Cited by 69

Small molecules targeting protein–protein interactions for cancer therapy

Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML

Valent, P., Sadovnik, I., Eisenwort, G., Bauer, K., Herrmann, H., Gleixner, K. V., Schulenburg, A., Rabitsch, W., Sperr, W. R., & Wolf, D. G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174233 · Cited by 60

PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer

Darga, E. P., Dolce, E. M., Fang, F., Kidwell, K., Gersch, C. L., Kregel, S., Thomas, D. G., Gill, A., Brown, M. E., Gross, S. C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260124 · Cited by 59

Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold

Qin, M., Cao, Q., Wu, X., Liu, C., Zheng, S., Xie, H., Tian, Y., Xie, J., Zhao, Y., Hou, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111856 · Cited by 59

New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

Jin, H., Qin, S., He, J., Xiao, J., Li, Q., Mao, Y., & Zhao, L. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70691 · Cited by 58

A Dual Role of Type I Interferons in Antitumor Immunity

Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 62

Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma

Li, X.-Y., Tan, L.-C., Dong, L.-W., Zhang, W.-Q., Shen, X.-X., Lu, X., Zheng, H., & Lu, Y.-G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00597 · Cited by 55

HDACs and the epigenetic plasticity of cancer cells: target the complexity

Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55

A QSP model of prostate cancer immunotherapy to identify effective combination therapies

Coletti, R., Leonardelli, L., Parolo, S., & Marchetti, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-65590-0 · Cited by 55

Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy

Yao, Y., Chen, H., & Tan, N. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.010 · Cited by 54

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer

Jiang, C., Cao, S., Li, N., Jiang, L., & Sun, T. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0955-2 · Cited by 51

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer

Liu, X., Xi, X., Xu, S., Chu, H., Hu, P., Li, D., Zhang, B., Liu, H., Jiang, T., & Lu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1507501 · Cited by 52

STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer

Shi, J., Liu, C., Luo, S., Cao, T., Lin, B., Zhou, M., Zhang, X., Wang, S., Zheng, T., & Li, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104384 · Cited by 52

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer

Zhao, Q. S., He, X., Qin, X., Liu, Y., Jiang, H., Wang, J., Wu, S., Zhou, R., Yu, C., Liu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938439 · Cited by 51

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition

Gu, C., Zhu, H., Deng, L., Meng, X., Li, K., Xu, W., Zhao, L., Liu, Y., Zhu, Z., & Huang, H. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00683-8 · Cited by 49

High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer

Engerud, H., Berg, H. F., Myrvold, M., Halle, M. K., Bjørge, L., Haldorsen, I. S., Høivik, E. A., Trovik, J., & Krakstad, C. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.020 · Cited by 49

Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug

Shen, N., Yang, C., Zhang, X., Tang, Z., & Chen, X. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.08.013 · Cited by 49

Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway

Lu, Y., Zhong, W., Liu, Y., chen, W., zhang, J., Zeng, Z., Huang, H., qiao, Y., Wan, X., Meng, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108504 · Cited by 48

A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma

Zhang, Y., He, R. L., Xuan, L., Mao, L., Jiang, P., Ni, C., Yin, Z., Zhong, X., Chen, C., Zheng, Q., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.780780 · Cited by 45

Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer

He, S., Song, W., Cui, S., Li, J., Jiang, Y., Chen, X., & Peng, L. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00839-0 · Cited by 47

PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications

Ulisse, S., Tuccilli, C., Sorrenti, S., Antonelli, A., Fallahi, P., D’Armiento, E., Catania, A., Tartaglia, F., Amabile, M. I., Giacomelli, L., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061405 · Cited by 46

Prenylated flavonoids in foods and their applications on cancer prevention

Wen, L., Zhou, T., Jiang, Y., Chang, S. K., & Yang, B. J. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1881437 · Cited by 47

The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Sun, Y., Yang, Q., Shen, J., Wei, T., Shen, W., Zhang, N., Luo, P., & Zhang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745859 · Cited by 48

Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma

Jeske, S. S., Schuler, P. J., Doescher, J., Theodoraki, M., Laban, S. A., Brunner, C., Hoffmann, T. K., & Wigand, M. C. C. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-0174-7 · Cited by 46

LEGENDplex™: Bead-assisted multiplex cytokine profiling by flow cytometry

Lehmann, J. S., Rughwani, P., Kolenovic, M., Ji, S., & Sun, B. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.06.001 · Cited by 44

Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism

Costa, L. B., Queiroz, M. A., Barbosa, F. D. G., Nunes, R. F., Zaniboni, E. C., Ruiz, M. F. D. C. M., Jardim, D. L. F., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2020) · Radiographics · doi:10.1148/rg.2021200093 · Cited by 44

Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy

Cai, H., Zhang, Y., Zhang, H., Cui, C., Li, C., & Lu, S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25859 · Cited by 43

Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer

He, R. L., Man, C., Huang, J., He, L., Wang, X., Lang, Y., & Fan, Y. J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.870945 · Cited by 43

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies

Dong, Y., Wan, Z., Gao, X., Yang, G., & Liu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609762 · Cited by 45

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

Wang, S., Zhou, X., Zeng, Z., Sui, M., Chen, L., Feng, C., Huang, C. Y., Yang, Q., Ji, M., & Hou, P. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01034-9 · Cited by 43

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities

Dai, M., Liu, M., Yang, H., Küçük, C., & You, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00356-0 · Cited by 46

Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

Zhang, X., Yang, Z., An, Y., Liu, Y., Wei, Q., Xu, F., Yao, H., & Zhang, Z. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02549-7 · Cited by 42

Reshaping Antitumor Immunity with Chemo‐Photothermal Integrated Nanoplatform to Augment Checkpoint Blockade‐Based Cancer Therapy

Gao, T., Zhang, Z., Liang, S., Fu, S., Mu, W., Guan, L., Liu, Y., Chu, Q., Fang, Y., Liu, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100437 · Cited by 41

Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer

Ri, M., Ma, J., & Jin, X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114370 · Cited by 41

PET imaging of immune checkpoint proteins in oncology

Bouleau, A., Lebon, V., & Truillet, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107786 · Cited by 40

Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy

Chen, H., Zhang, P., Shi, Y., Liu, C., Zhou, Q., Zeng, Y., Cheng, H., Dai, Q., Gao, X., Wang, X., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01266-3 · Cited by 40

Self-Assembly Catalase Nanocomplex Conveyed by Bacterial Vesicles for Oxygenated Photodynamic Therapy and Tumor Immunotherapy

Zhang, J., Li, Z., Liu, L., Li, L., Zhang, L., Wang, Y., & Zhao, J. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s353330 · Cited by 40

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer

Wang, Z., Zhu, M., Dong, R., Cao, D., Li, Y., Chen, Z., Cai, J., & Zuo, X. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02203-8 · Cited by 40

29 immune-related genes pairs signature predict the prognosis of cervical cancer patients

Nie, H., Bu, F., Xu, J., Li, T., & Huang, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-70500-5 · Cited by 39

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy

Shen, L., Wang, B., Wang, S., Ji, S., Fu, M., Wang, S.-W., Hou, W., Dai, X., & Liu, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02133 · Cited by 39

The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer

Weng, Y., Yuan, J., Cui, X., Wang, J., Chen, H., Li, X., Chen, X., Peng, M., & Song, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-64980-y · Cited by 40

Protein homodimer sequestration with small molecules: Focus on PD-L1

Bailly, C., & Vergoten, G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113821 · Cited by 38

T‐cells expressing a chimeric‐PD1‐Dap10‐CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer

Parriott, G., Deal, K., Crean, S., Richardson, E., Nylen, E., & Barber, A. E. (2020) · Immunology · doi:10.1111/imm.13187 · Cited by 37

Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy

Wan, C., Sun, Y., Hu, Y., Huang, J., Lu, L., Gao, Y., Zi, H., He, Q., Sun, J., Lovell, J. F., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101323 · Cited by 37

Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats

Bouleau, A., Nozach, H., DuBois, S. G., Kereselidze, D., Chevaleyre, C., Wang, C., Evans, M. J., Lebon, V., Maillère, B., & Truillet, C. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262967 · Cited by 37

PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes

Li, X., Zhong, T., Tang, R., Wu, C., Xie, Y., Liu, F., & Zhou, Z. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa130 · Cited by 36

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

Jiang, Y., Wang, Z., Zhong, M., Shen, L., Han, X., Zou, X., Liu, X.-Y., Deng, Y.-N., Yang, Y., Chen, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908010 · Cited by 37

Out of the Curricular Shadows: Revolutionizing Undergraduate Immunology Education

Bruns, H. A., Deaver, J., & Justement, L. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02446 · Cited by 35

Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma

Gao, L., Xia, L., Ji, W., Zhang, Y., Xia, W., & Lü, S. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101148 · Cited by 37

Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%

Kuznik, A., Smare, C., Chen, C.-I., Venkatachalam, M., Keeping, S., Atsou, K., Xu, Y., Wilson, F. R., Guyot, P., Chan, K., et al. (2021) · Value in Health · doi:10.1016/j.jval.2021.08.009 · Cited by 36

Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction

Wu, Y., Zhang, Y. X., Guo, Y. L., Pan, Z., Zhong, S., Jin, X., Zhuang, W., Chen, S., Gao, J., Huang, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113637 · Cited by 34

Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications

Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022) · Immunology · doi:10.1111/imm.13573 · Cited by 38

WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers

Jin, M.-H., Nam, A., Bang, J., Oh, K.-S., Seo, H.-R., Kim, J.-M., Yoon, J., Kim, T., & Oh, D. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01176-7 · Cited by 33

Immune Checkpoint Inhibitors in the Treatment of Cancer

Zam, W., & Ali, L. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210325095022 · Cited by 33

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis

Liu, Y., Zhang, X., Wang, G., & Cui, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693655 · Cited by 32

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Zhang, K., Kong, X., Li, Y., Wang, Z., Zhang, L., & Xuan, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854967 · Cited by 34

Cancer Immunotherapy Beyond PD1/PD-L1

Dr. D. Rama Bramha Reddy, K. M. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.21927064

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,307

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 19

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Abaza, A., Sid Idris, F., Anis Shaikh, H., Vahora, I., Moparthi, K. P., Al Rushaidi, M. T., Muddam, M. R., Obajeun, O. A., Jaramillo, A. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.44582 · Cited by 59

Overview of PD-1 and PD-L1 Inhibitors

Andreatos, N., Bhatia, S., & Grivas, P. D. (2019) · Springer Publishing Company eBooks · doi:10.1891/9780826172150.0002